Canada: Pharmaceutical Data Protection In Canada: The Latest Word From Photocure

In the recent Photocure1 decision the Federal Court has once again sided with Canada's Minister of Health in denying data protection for a new medicinal ingredient. In Photocure, the medicinal ingredient was labelled "a variation" of a previously approved medicinal ingredient. While Photocure presented expert evidence to the contrary, the Court refused to consider the evidence, refusing data protection in the process and opening the door to generic copying of Photocure's data filed with its New Drug Submission. This case presents an opportunity to examine the Minister's unbeaten track record in data protection judicial review applications and consider how we arrived at the present state of affairs.

Background on Data Protection

In 2006, Canada amended the data protection provisions of the Food and Drug Regulations to grant eight years of market exclusivity to manufacturers of "innovative drugs." These amendments were intended to clarify and effectively implement Canada's obligations under the North American Free Trade Agreement and the Agreement on Trade-Related Aspects of Intellectual Property Rights to protect undisclosed data necessary to determine the safety and efficacy of a new pharmaceutical product containing a new chemical entity. As determined by the Federal Court of Appeal, the clear policy behind Canada's data protection regulations is to encourage the development of new drugs.2

The eight years of market exclusivity is enforced through a six-year "no filing" period and an eight year "no approval" period. In the first six years, no one may file a drug submission making a direct or indirect comparison to the innovator's data.

In the last two years, a drug submission may be filed but the approval (i.e., the Notice of Compliance or NOC) cannot issue until the expiry of the eight-year term. This eight year "no approval" period is extended an additional six months if pediatric studies are filed. The "no approval" period is also engaged when later-filed amendments to a drug submission make reference to an innovator's data.3 Drugs that qualify for data protection are listed on Health Canada's Register of Innovative Drugs.4

Eligibility for data protection is governed by the definition of "innovative drug" under the Food and Drug Regulations. The definition sets out what is not an innovative drug: an innovative drug contains a medicinal ingredient that is not (1) previously approved in a drug by the Minister and (2) a variation of a previously approved medicinal ingredient, such as a salt, ester, enantiomer, solvate or polymorph.

The Food and Drug Regulations do not provide further guidance regarding the meaning of "previously approved" or "a variation." Therefore, these terms are left for the Minister and the Courts to interpret and apply. Since 2006, a series of decisions from the Federal Court and Federal Court of Appeal have tackled the meaning of these terms.

Three decisions of the Federal Court and Federal Court of Appeal have addressed the meaning of "previously approved":

  • In Epicept (histamine dihydrochloride),5 the Federal Court determined that "previously approved in a drug" includes approvals in any drug (e.g., natural health products) and is not limited to approvals of "new drugs" through the drug submission and NOC procedures. This decision is reflected in the Minister's data protection analysis, where the Minister searches a number of databases for previously approved medicinal ingredients, such as the Drug Product Database and the Licensed Natural Health Products Database. Notably, the Minister's search is not limited to the NOC Database, which lists approvals of "new drugs."
  • In Teva (oxaliplatin),6 the Federal Court of Appeal determined that authorizations under Canada's Special Access Programme do not constitute "approvals" and therefore do not act as a bar to later data protection.
  • In Celgene (thalidomide),7 the Federal Court of Appeal determined that "previously" does not mean "currently" and therefore it is irrelevant if the approval of the "previously approved" drug was subsequently revoked. The medicinal ingredient at issue in Celgene, thalidomide, was approved in the 1960s, but was subsequently pulled from the market for serious side-effects in pregnant women. This subsequent removal from the market did not impact thalidomide's "previously approved" status.

The Federal Court has also addressed the meaning of "a variation." In Takeda (dexlansoprazole),8 notwithstanding a strong dissent to the contrary, the majority of the Federal Court of Appeal found that the enumerated variations (i.e., salt, ester, enantiomer, solvate or polymorph) of previously approved medicinal ingredients are automatically excluded from data protection, irrespective of the nature of the underlying data or what it demonstrates with respect to the medicinal ingredient under review.

This restrictive interpretation of "innovative drug" puts Canada at odds with the law of the United States and the European Union. In the US, data protection is available for drugs that "demonstrate substantial evidence of effectiveness of a previously approved drug product for any indication or of safety for a new patient population." Similarly, in the EU, data protection is available for drugs that are variations of previously approved drugs but differ "significantly in properties with regard to safety and efficacy."

In Canada, while the regulatory basis (and clearly the policy basis) exists for an analysis of safety and efficacy, medicinal ingredients labelled as one of the enumerated "variations" have not to date benefitted from such a review.

Recent Application of "a variation" in Photocure

This restrictive interpretation of "variations" was recently illustrated in the Federal Court's decision in Photocure.9 The drug at issue was Photocure's new drug CYSVIEW, an optical imaging agent designed to enhance detection of bladder cancer. The medicinal ingredient in CYSVIEW is hexaminolevulinate hydrochloride (referred to in the decision as "HAL HCl").

The Minister found CYSVIEW ineligible for data protection because HAL HCl was deemed to be an ester variation of a previously approved medicinal ingredient, aminolevulinic acid hydrochloride (referred to in the decision as "ALA HCl"). The Minister understood that the structure of HAL HCl is identical to ALA HCl, but with the addition of an ester group. Accordingly, CYSVIEW was automatically excluded from data protection, irrespective of the clinical data contained in the drug submission.

Photocure challenged the Minister's finding in a judicial review application to the Federal Court, arguing that the material issue was one of interpretation of "innovative drug," However, the Court disagreed and found that the issue before the Court was the narrow question of whether HAL HCl is an ester of ALA HCl, declaring the issue to be the proper application of the regulations and not the meaning of the regulations.

Different Standard of Review Applied

The Court considered the standard of review in Photocure to be the deferential standard of reasonableness. This case is the first data protection judicial review to apply such a standard; all prior cases have applied the standard of correctness. The Court distinguished the established line of authority on the basis that questions of statutory interpretation were raised in those cases, while this case dealt merely with a question of fact.

It should be noted that even more recently, in Hospira, the Federal Court reverted to the logic of previous decisions, finding that the standard of review is correctness.10 It may be that the Court's decision in Photocure is an outlier in terms of standard of review.

Subsequently-Filed Evidence found Inadmissible

Prior to assessing the merits of the application, the Court applied an evidentiary rule unique to judicial review proceedings and rejected expert affidavit evidence filed by Photocure and also responding evidence filed by the Minister. The evidence related to issues of science. For example, Photocure's expert stated that chemists would regard HAL HCI as first a salt of HAL and secondly as an ester of ALA.

The Minster objected to Photocure's expert evidence, arguing that evidence in judicial review applications must be limited to the evidence before the administrative decision-maker. There are exceptions to this rule, including an exception allowing general background evidence, and Photocure argued that its expert evidence was permissible under this exception.

The Court disagreed, noting that Photocure's expert "opines on the very issue the Minister was asked to determine" and "attempts to impugn the decision after the fact with information that was not provided to the decision-maker." For this reason, Photocure's expert evidence was struck, as was the Minister's responding evidence.

Minister's Decision Found Reasonable

The Court in Photocure went on to find the Minister's denial of data protection for CYSVIEW to be reasonable. Without the impugned, but contradicting, expert evidence in hand the Court found that the Minister's decision fell within a range of possible, acceptable outcomes, and was therefore reasonable.

To date, the Federal Court's decisions have reflected the Minister's restrictive interpretation of the definition of "innovative drug" and the Minister's restrictive approach to data protection. Nevertheless, the precise scope of the Regulations, and of data protection in Canada, remains to be determined.

Footnotes

1 Photocure ASA v Canada, 2015 FC 959.

2 Apotex Inc v Canada (Health), 2010 FCA 334.

3 Hospira Healthcare Corporation v Canada (Health), 2015 FC 1205.

4 Available online: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/regist/reg_innov_dr-eng.php.

5 Epicept Corporation v Canada (Health), 2010 FC 956.

6 Teva Canada Limited v Canada (Health), 2012 FCA 106.

7 Canada (Health) v Celgene Inc, 2013 FCA 43.

8 Takeda Canada Inc v Canada, 2013 FCA 13.

9 Photocure ASA v Canada, 2015 FC 959.

10 Hospira Healthcare Corporation v Canada (Health), 2015 FC 1205.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions